AAPL   269.21 (+1.37%)
FB   200.39 (+0.52%)
MSFT   150.68 (+0.50%)
GOOGL   1,339.12 (+1.53%)
AMZN   1,752.57 (-0.46%)
CGC   18.65 (+0.27%)
NVDA   212.04 (+1.25%)
MU   48.09 (+3.15%)
BABA   200.51 (+0.26%)
GE   10.98 (+1.76%)
TSLA   338.28 (+1.58%)
T   38.37 (+0.47%)
AMD   39.94 (+0.63%)
PRI   136.22 (+1.43%)
NFLX   304.56 (+0.08%)
GILD   66.82 (+0.10%)
DIS   147.73 (+0.20%)
AAPL   269.21 (+1.37%)
FB   200.39 (+0.52%)
MSFT   150.68 (+0.50%)
GOOGL   1,339.12 (+1.53%)
AMZN   1,752.57 (-0.46%)
CGC   18.65 (+0.27%)
NVDA   212.04 (+1.25%)
MU   48.09 (+3.15%)
BABA   200.51 (+0.26%)
GE   10.98 (+1.76%)
TSLA   338.28 (+1.58%)
T   38.37 (+0.47%)
AMD   39.94 (+0.63%)
PRI   136.22 (+1.43%)
NFLX   304.56 (+0.08%)
GILD   66.82 (+0.10%)
DIS   147.73 (+0.20%)
AAPL   269.21 (+1.37%)
FB   200.39 (+0.52%)
MSFT   150.68 (+0.50%)
GOOGL   1,339.12 (+1.53%)
AMZN   1,752.57 (-0.46%)
CGC   18.65 (+0.27%)
NVDA   212.04 (+1.25%)
MU   48.09 (+3.15%)
BABA   200.51 (+0.26%)
GE   10.98 (+1.76%)
TSLA   338.28 (+1.58%)
T   38.37 (+0.47%)
AMD   39.94 (+0.63%)
PRI   136.22 (+1.43%)
NFLX   304.56 (+0.08%)
GILD   66.82 (+0.10%)
DIS   147.73 (+0.20%)
AAPL   269.21 (+1.37%)
FB   200.39 (+0.52%)
MSFT   150.68 (+0.50%)
GOOGL   1,339.12 (+1.53%)
AMZN   1,752.57 (-0.46%)
CGC   18.65 (+0.27%)
NVDA   212.04 (+1.25%)
MU   48.09 (+3.15%)
BABA   200.51 (+0.26%)
GE   10.98 (+1.76%)
TSLA   338.28 (+1.58%)
T   38.37 (+0.47%)
AMD   39.94 (+0.63%)
PRI   136.22 (+1.43%)
NFLX   304.56 (+0.08%)
GILD   66.82 (+0.10%)
DIS   147.73 (+0.20%)
Log in

NYSE:PEN - Penumbra Stock Price, Forecast & News

$170.34
+0.77 (+0.45 %)
(As of 12/6/2019 10:05 AM ET)
Today's Range
$170.01
Now: $170.34
$171.61
50-Day Range
$145.47
MA: $163.48
$177.80
52-Week Range
$110.84
Now: $170.34
$185.70
Volume5,840 shs
Average Volume453,080 shs
Market Capitalization$5.95 billion
P/E Ratio334.00
Dividend YieldN/A
Beta0.76
Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone510-748-3200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$444.94 million
Cash Flow$0.68 per share
Book Value$12.24 per share

Profitability

Net Income$6.60 million

Miscellaneous

Employees2,200
Market Cap$5.95 billion
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive PEN News and Ratings via Email

Sign-up to receive the latest news and ratings for PEN and its competitors with MarketBeat's FREE daily newsletter.


Penumbra (NYSE:PEN) Frequently Asked Questions

What is Penumbra's stock symbol?

Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."

How were Penumbra's earnings last quarter?

Penumbra Inc (NYSE:PEN) released its quarterly earnings data on Thursday, November, 7th. The company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.18 by $0.07. The business had revenue of $139.50 million for the quarter, compared to analyst estimates of $133.98 million. Penumbra had a net margin of 8.69% and a return on equity of 7.23%. The business's revenue for the quarter was up 24.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.17 EPS. View Penumbra's Earnings History.

When is Penumbra's next earnings date?

Penumbra is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Penumbra.

What price target have analysts set for PEN?

7 analysts have issued twelve-month price targets for Penumbra's stock. Their forecasts range from $180.00 to $200.00. On average, they expect Penumbra's share price to reach $191.40 in the next twelve months. This suggests a possible upside of 12.9% from the stock's current price. View Analyst Price Targets for Penumbra.

What is the consensus analysts' recommendation for Penumbra?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Penumbra.

Has Penumbra been receiving favorable news coverage?

News headlines about PEN stock have trended somewhat negative this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Penumbra earned a daily sentiment score of -1.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Penumbra.

Are investors shorting Penumbra?

Penumbra saw a decrease in short interest in the month of October. As of October 31st, there was short interest totalling 5,530,000 shares, a decrease of 13.9% from the September 30th total of 6,420,000 shares. Based on an average trading volume of 562,100 shares, the days-to-cover ratio is presently 9.8 days. Approximately 17.2% of the shares of the company are sold short. View Penumbra's Current Options Chain.

Who are some of Penumbra's key competitors?

What other stocks do shareholders of Penumbra own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include Netflix (NFLX), NVIDIA (NVDA), Alibaba Group (BABA), Intuitive Surgical (ISRG), Splunk (SPLK), salesforce.com (CRM), DexCom (DXCM), Paypal (PYPL), Twilio (TWLO) and Adobe (ADBE).

Who are Penumbra's key executives?

Penumbra's management team includes the folowing people:
  • Mr. Adam Elsesser, Co Founder, Chairman, CEO & Pres (Age 57)
  • Dr. Arani Bose, Co-Founder, Chief Innovator and Director (Age 57)
  • Mr. Sridhar N. Kosaraju, CFO and Head of Strategy (Age 41)
  • Ms. Lynn Rothman, Chief Bus. Officer and Exec. VP (Age 58)
  • Mr. Daniel Donen Davis, Chief Commercial Officer (Age 41)

Who are Penumbra's major shareholders?

Penumbra's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include State Street Corp (2.36%), Stephens Investment Management Group LLC (0.88%), Great Point Partners LLC (0.86%), Redmile Group LLC (0.85%), Ardevora Asset Management LLP (0.70%) and Eagle Asset Management Inc. (0.65%). Company insiders that own Penumbra stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Coyne David, Daniel Donen Davis, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Robert D Evans, Sridhar Kosaraju and Thomas Wilder. View Institutional Ownership Trends for Penumbra.

Which institutional investors are selling Penumbra stock?

PEN stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Squarepoint Ops LLC, First Trust Advisors LP, Calamos Advisors LLC, Barclays PLC, Chicago Equity Partners LLC, Lisanti Capital Growth LLC and Congress Asset Management Co. MA. Company insiders that have sold Penumbra company stock in the last year include Adam Elsesser, Arani Bose, Bridget O'rourke, Don W Kassing, Harpreet Grewal, James Robert Pray, Lynn Rothman, Sridhar Kosaraju and Thomas Wilder. View Insider Buying and Selling for Penumbra.

Which institutional investors are buying Penumbra stock?

PEN stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Great Point Partners LLC, Redmile Group LLC, Point72 Asset Management L.P., Rhumbline Advisers, Columbus Circle Investors, Retirement Systems of Alabama and State of New Jersey Common Pension Fund D. View Insider Buying and Selling for Penumbra.

How do I buy shares of Penumbra?

Shares of PEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Penumbra's stock price today?

One share of PEN stock can currently be purchased for approximately $169.57.

How big of a company is Penumbra?

Penumbra has a market capitalization of $5.92 billion and generates $444.94 million in revenue each year. The company earns $6.60 million in net income (profit) each year or $0.51 on an earnings per share basis. Penumbra employs 2,200 workers across the globe.View Additional Information About Penumbra.

What is Penumbra's official website?

The official website for Penumbra is http://www.penumbrainc.com/.

How can I contact Penumbra?

Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The company can be reached via phone at 510-748-3200 or via email at [email protected]


MarketBeat Community Rating for Penumbra (NYSE PEN)

Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  577 (Vote Outperform)
Underperform Votes:  201 (Vote Underperform)
Total Votes:  778
MarketBeat's community ratings are surveys of what our community members think about Penumbra and other stocks. Vote "Outperform" if you believe PEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/6/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel